The Charles River Frontage acquisition was announced on November 9, 2026, when Charles River Laboratories International, Inc. (NYSE: CRL) said it had signed definitive agreements to buy the bioanalysis and DMPK operations of Frontage Holdings Corporation in Exton, Pennsylvania. The company will pay approximately $470 million in cash, subject to customary closing adjustments.
In addition to the upfront price, the Charles River Frontage acquisition includes contingent payments of up to $75 million tied to the future performance of the acquired businesses. Closing is expected during the first half of 2027, subject to required shareholder and regulatory approvals and other customary closing conditions. The release does not detail the performance measures that would trigger the contingent payments.
Chief Executive Officer Birgit Girshick said the planned deal accelerates the company’s strategy of expanding its bioanalysis capabilities in an attractive, high-growth market. She noted that biologics and increasingly complex modalities are taking up a larger share of development pipelines. Clients, she said, want scientific partners that can support programs from early development through the clinic, and Frontage’s clinical bioanalysis expertise, scientific team and client relationships are meant to help meet that need.
Charles River Frontage Acquisition: Deal Terms and Acquired Laboratory Footprint
Under the disclosed terms, the Charles River Frontage acquisition covers Frontage’s laboratory testing sites that provide bioanalysis, biomarker and DMPK (drug metabolism and pharmacokinetics) testing for large and small molecules. These services primarily support clinical development programs for biopharmaceutical clients. The perimeter includes a CLIA-certified central laboratory and two sites in Exton, Pennsylvania.
The two Exton sites operate across approximately 150,000 square feet and employ approximately 340 people. Girshick said Charles River looks forward to welcoming the Frontage bioanalysis and DMPK team. She described the combined offering as a more integrated solution that should accelerate development timelines and improve continuity from preclinical through clinical testing.
Readers should note that the deal is a carve-out rather than a purchase of the whole company. Frontage is listed on The Stock Exchange of Hong Kong, and only its bioanalysis and DMPK businesses in Exton will end up with Charles River. Frontage’s remaining businesses go to other parties, as explained in the structure section below.
Charles River Frontage Acquisition Expands Clinical Bioanalysis Capabilities
Charles River frames the Charles River Frontage acquisition as a step in its Pathway to Purpose strategy. The release says the transaction expands the company’s presence in clinical bioanalysis and strengthens its scientific leadership. It also complements Charles River’s existing preclinical bioanalysis strength, which is primarily in biologics and complex modalities, while adding scale and capacity to support future growth.
Market sizing is central to the rationale. Charles River expects the bioanalysis sector to grow from approximately $6 billion in 2026 to approximately $8 billion to $9 billion in 2031, an annual growth rate of 6% to 8%. It anticipates faster growth in biologics, complex modalities and clinical-phase testing. These are company projections, not independently verified figures.
Clinical exposure is where the Charles River Frontage acquisition changes the revenue mix most. Today approximately 15% of Charles River’s bioanalysis revenue comes from clinical-phase testing, while the majority of Frontage’s bioanalysis revenue in 2025 was generated during clinical development. Charles River expects a more balanced portfolio to strengthen client relationships, increase share of wallet and improve retention across longer clinical programs, including late-stage clinical diagnostic testing.
Charles River Frontage Acquisition Financial Impact and DSA Segment Reporting
On modalities, biologics and complex modalities account for approximately 75% of Charles River’s bioanalysis revenue, and the company calls them the fastest-growing segments of the sector. Frontage’s expertise is expected to complement that base while broadening small molecule bioanalysis capabilities. Management also expects synergies across the Discovery and Safety Assessment (DSA) and Manufacturing Solutions segments.
The financial profile of the Charles River Frontage acquisition is laid out in modest detail. The acquired businesses represented approximately 40% of Frontage’s total 2025 revenue of $256.7 million. Charles River expects their revenue to grow at the projected bioanalysis sector growth rate over the next five years. Standalone profit figures for the acquired businesses were not disclosed.
On earnings, the company expects the transaction to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter. Excluded items are expected to include acquisition-related costs, mainly amortization of intangible assets, advisory fees, certain efficiency-initiative costs and certain third-party integration costs. The Charles River Frontage acquisition and associated fees will be financed through Charles River’s credit facility and available cash, and the acquired businesses are expected to be reported within the DSA segment.
Charles River Frontage Acquisition Deal Terms
| Attribute | Detail |
|---|---|
| Announcement date | November 9, 2026 |
| Acquirer | Charles River Laboratories International, Inc. (NYSE: CRL) |
| Target businesses | Frontage Holdings Corporation’s bioanalysis and DMPK operations, Exton, Pennsylvania |
| Upfront consideration | Approximately $470 million in cash, subject to customary closing adjustments |
| Contingent consideration | Up to $75 million, based on future performance of the acquired businesses |
| Expected closing | First half of 2027 |
| Closing conditions | Required shareholder and regulatory approvals and other customary conditions |
| Financing | Charles River credit facility and available cash |
| Reporting segment | Discovery and Safety Assessment (DSA) |
| Earnout performance metrics | Not disclosed |
